Incyte rises after blood cancer drug succeeds in early-stage trial

** Drugmaker Incyte's INCY.O shares rise 4.4% to $79.69

** INCY said on Sunday its experimental blood cancer treatment showed it could target and remove cancer cells while leaving healthy cells intact, potentially restoring normal blood production

** The therapy treats a group of blood disorders where a specific gene mutation causes blood cells to multiply uncontrollably

** 86% of patients on higher doses of the experimental therapy showed significant improvement in blood cell counts, with most (82%) achieving complete normalization of their previously elevated platelet levels

** INCY plans to meet with regulators and aims to start late-stage testing by early 2026

** Including session's moves, INCY stock down up 0.9% YTD